Xin Lang Cai Jing·2026-02-06 15:27Core Viewpoint - Hims & Hers Health has launched a compounded semaglutide pill priced at $49, causing a 6.2% drop in its stock and putting pressure on competitors Novo Nordisk and Eli Lilly, with Novo Nordisk planning legal action against the compounded drug practices [1][1]. Company Summary - Hims & Hers Health's stock fell by 6.2% following the introduction of a compounded semaglutide pill [1]. - The new product is priced at $49, which is significantly lower than existing options in the market [1]. Industry Summary - The launch of the compounded semaglutide pill by Hims & Hers Health is expected to create competitive pressure on major pharmaceutical companies like Novo Nordisk and Eli Lilly [1]. - Novo Nordisk has vowed to take legal action against the large-scale compounded drug practices initiated by Hims & Hers Health [1].